Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates
Journal of Controlled Release · 2023
DOI: 10.1016/j.jconrel.2023.06.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Parvin Zamani und 17 weiteren Autor:innen. Beteiligte Einrichtung: Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceuti…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
mRNA-lipid nanoparticle (mRNA-LNP) vaccines have proved their efficacy, versatility and unprecedented manufacturing speed during the COVID-19 pandemic. Here we report on the physicochemical properties, thermostability, immunogenicity, and protective efficacy of the nucleoside-modified mRNA-LNP vaccine candidate Iribovax® (also called SNEG2c). Injection of BALB/c mice, rabbits and nonhuman primates with two doses of SNEG2c induced production of high-titers of SARS-CoV-2 spike-specific and receptor-binding domain (RBD)-neutralizing antibodies in immunized animals. In addition to the strong humoral response, SNEG2c elicited substantial Th1-biased T-cell response. Sera from rhesus macaques immunized with a low dose of the vaccine showed robust spike-specific antibody titers 3-24× as high as those in convalescent sera from a panel of COVID-19 patients and 50% virus neutralization geometric mean titer of 1024 against SARS-CoV-2. Strikingly, immunization with SNEG2c completely cleared infectious SARS-CoV-2 from the upper and lower respiratory tracts of challenged macaques and protected them from viral-induced lung and trachea lesions. In contrast, the non-vaccinated macaques developed moderate to severe pulmonary pathology after the viral challenge. We present the results of repeat-dose and local tolerance toxicity and thermostability studies showing how the physicochemical properties of the mRNA-LNPs change over time and demonstrating that SNEG2 is safe, well tolerated and stable for long-term. These results support the planned human trials of SNEG2c.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical…
- Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Stem Cell Biology and Regenerative Medicine Research Group, Research Institute of Biotechnology…
- Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
- Pasteur Institute of Iran, Department of Hepatitis and AIDS, Tehran, Iran; Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran.
- Department of Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran; Institute of Biomedical Research, University of Tehran, Tehran, Iran.
Zitieren
APA
Zamani, P., Mashreghi, M., Rezazade Bazaz, M., Zargari, S., Alizadeh, F., Dorrigiv, M., Abdoli, A., Aminianfar, H., Hatamipour, M., Zarqi, J., Behboodifar, S., Samsami, Y., Khorshid Sokhangouy, S., Sefidbakht, Y., Uskoković, V., Rezayat, S. M., Jaafari, M. R., & Mozaffari-Jovin, S. (2023). Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.06.025
Vancouver
Zamani P, Mashreghi M, Rezazade Bazaz M, Zargari S, Alizadeh F, Dorrigiv M, et al. Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.06.025
BibTeX
@article{Zamani2023,
author = {Zamani, Parvin and Mashreghi, Mohammad and Rezazade Bazaz, Mahere and Zargari, Selma and Alizadeh, Farzaneh and Dorrigiv, Mahyar and Abdoli, Asghar and Aminianfar, Hossein and Hatamipour, Mahdi and Zarqi, Javad and Behboodifar, Saeed and Samsami, Yalda and Khorshid Sokhangouy, Saeideh and Sefidbakht, Yahya and Uskoković, Vuk and Rezayat, Seyed Mahdi and Jaafari, Mahmoud Reza and Mozaffari-Jovin, Sina},
title = {Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates},
journal = {Journal of Controlled Release},
year = {2023},
doi = {10.1016/j.jconrel.2023.06.025}
}
EUVIMED